Live Breaking News & Updates on Shachar Hadar

Stay updated with breaking news from Shachar hadar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Perion Network : FORM S-8-REGISTRATION STATEMENT

As filed with the United States Securities and Exchange Commission


on May 2 ,2024


Registration No. 333-


. ....

Washington , United-states , Israel , New-york , Tel-aviv , Ramat-gan , Israeli , State-of-israel , Eyal-kaplan , Elad-ziv , Shachar-hadar , Maoz-sigron

Scisparc : At-The-Market Issuance Sales Agreement - Form 6-K

At-The-Market Issuance Sales Agreement


May 16, 2023


Aegis Capital Corp.


1345 Avenue of the Americas, 27th Floor


New York, New. | May 17, 2023 ....

New-york , United-states , City-of-new-york , Israel , Sudan , Iran , Myanmar , Abba-hillel , Hadarom , Ramat-gan , Tel-aviv , Cuba

Between Sacred and Profane | Israel Today


With the truth that rages within me
With a thousand habits
I go out again to scatter the words
Between reality and madness, it’s all coming back to me
The place from whence I came has no peace
And this journey is heavy and a little too much for me
I need to grow through it and that’s it
To grow through it and that’s it
I live between the sacred and the profane
Between the truth that rages within me
With a thousand habits
I go out again to scatter the words
Between reality and madness, it’s all coming back to me ....

Israel , Israeli , Shuli-rand , Shachar-hadar , Amir-dadon , இஸ்ரேல் , இஸ்ரேலி , அமீர்-ததொந் ,

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement


Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need
Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel
CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, announce their entry into a definitive merger agreement pursuant to which the shareholders ....

Israel , Cambridge , Cambridgeshire , United-kingdom , Anchiano-adss , Ronen-bezalel , Stan-polovets , Neil-cohen , Peter-thiel , Shachar-hadar , Goldfarb-seligman , Stephen-squinto